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Abstract
Background: Disturbances in lipid homeostasis and myelination have been proposed in the
pathophysiology of schizophrenia and bipolar disorder. We have previously shown that several
antipsychotic and antidepressant drugs increase lipid biosynthesis through activation of the Sterol
Regulatory Element-Binding Protein (SREBP) transcription factors, which control the expression of
numerous genes involved in fatty acid and cholesterol biosynthesis. The aim of the present proof-
of-principle study was to investigate whether such drugs also affect lipid transport and export
pathways in cultured human CNS and liver cells.
Results: Quantitative PCR and immunoblotting were used to determine the level of lipid transport
genes in human glioblastoma (GaMg) exposed to clozapine, olanzapine, haloperidol or imipramine.
The effect of some of these drugs was also investigated in human astrocytoma (CCF-STTG1),
neuroblastoma (SH-SY5Y) and hepatocellular carcinoma (HepG2) cells. We found significant
transcriptional changes of cholesterol transport genes (ApoE, ABCA1, NPC1, NPC2, NPC1L1), which
are predominantly controlled by the Liver X receptor (LXR) transcription factor. The up-
regulation was observed after 24 to 48 hours of drug exposure, which is markedly delayed as
compared to the drug-induced SREBP-controlled stimulation of lipid biosynthesis seen after 6
hours.
Conclusion:  Our data show that stimulation of cellular lipid biosynthesis by amphiphilic
psychotropic drugs is followed by a transcriptional activation of cholesterol transport and efflux
pathways. Such effects may be relevant for both therapeutic effects and metabolic adverse effects
of psychotropic drugs.
Background
Antipsychotic and antidepressant drugs are imperative in
the treatment of schizophrenia and affective disorders.
These drugs exert their therapeutic effects at least in part
through perturbation of the dopamine-, noradrenaline-
and serotonin neurotransmitter systems in the brain, but
additional molecular mechanisms of action are likely to
contribute to their clinical effect. We have demonstrated
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that several antipsychotics and antidepressants increase
lipid biosynthesis in cultured human CNS cells [1-4]. This
drug-induced stimulation of cellular lipogenesis could
represent a novel mechanism of psychotropic drug action
in the brain, since glia-produced lipids, including choles-
terol, play important roles in myelination and synap-
togenesis [5,6]. Interestingly, several studies have
indicated disrupted glial function, as well as lipid and
myelin abnormalities, in schizophrenia and affective dis-
orders [7-11]. The drug-mediated lipogenic effect could
also be relevant for the associated serious metabolic
adverse effects, such as weight gain and dyslipidemia.
Indeed, some of the psychotropic drugs increase the
expression of lipid biosynthesis genes in cultured hepato-
cytes and adipocytes [1,3,12-14], as well as in blood cells
from olanzapine-treated patients [15].
The increased lipid biosynthesis is mediated through acti-
vation of the sterol regulatory element-binding protein
(SREBP) transcription factors, which control the expres-
sion of genes involved in cellular production of choles-
terol (e.g., 3-hydroxy-3-methylglutaryl-CoA reductase;
HMGCR) and fatty acids (e.g., fatty acid synthase; FASN
and stearoyl CoA-desaturase; SCD). The SREBP system is
sensitive to cationic amphiphilic drugs, such as antipsy-
chotic and tricyclic antidepressant, through their ability to
partly mimic the effects of oxysterols [16].
A prolonged drug-induced stimulation of cellular lipo-
genesis would be expected to activate intracellular lipid
transport and export pathways. The Liver X Receptor
(LXR) transcription factor functions as an intracellular
oxysterol sensor and controls the expression of central
cholesterol transport proteins, such as apolipoprotein E
(ApoE), ATP-binding cassette transporter A1 (ABCA1)
and Niemann-Pick type C (NPC) protein, along with
other important factors in the cholesterol homeostasis of
the central nervous system and peripheral tissue [17,18].
The aim of this study was to determine if cationic
amphiphilic psychotropic drugs known to activate the
SREBP-system also have effects on the expression of LXR-
related lipid transport and export pathway genes in cul-
tured human CNS and liver cells.
Results
Human glioblastoma cells (GaMg) were exposed to cloz-
apine (25 μM), olanzapine (10 μM), haloperidol (10 μM)
and imipramine (10 μM) for 6, 12, 24 or 48 hours. The
choice of drugs and the different drug concentrations was
based on their structural similarity and our previous work
[1-4], but also taking into consideration the large differ-
ences in the clinical dosage of these drugs. As expected, all
the drugs induced a substantial early increase in mRNA
level of the SREBP-controlled 3-hydroxy-3-methylglutaryl-
CoA reductase (HMGCR) gene (Table 1), which is encod-
ing the rate-limiting enzyme in cholesterol biosynthesis.
Clearly delayed as compared to the increase in HMGCR,
we also observed a marked drug-mediated transcriptional
activation of the LXR-controlled genes ApoE, Niemann-
Pick type C1 (NPC1) and Niemann-Pick type C2 (NPC2),
reaching maximal values after 24-48 hours of drug expo-
sure with no significant response at 6 hours. ABCA1
expression diverged from the other LXR targets, with
haloperidol and in part imipramine mediating a signifi-
cant decrease in the mRNA level, whereas clozapine
induced a marked up-regulation at 48 hours (Table 1). We
also found that the gene encoding the LXR-isoform dom-
inant in CNS, LXRβ, was significantly up-regulated by
clozapine while down-regulated by haloperidol, although
the effect size was small. LXRα, which is a lesser expressed
isoform in the CNS, displayed a similar but non-signifi-
cant trend.
As shown in Figure 1, the drug effect on ApoE expression
was increased markedly from 1 μM to 10 μM, and clozap-
ine was apparently the most potent drug at the highest
concentration (25 μM). We also examined the protein
level of ApoE in GaMg cells exposed to a high dose (25
μM) of clozapine, olanzapine, haloperidol or imipramine
for 24 hours. All drugs induced a statistically significant
but moderate (1.4-1.5-fold) elevation of ApoE, as com-
pared to the control (Figure 1, right panel). We observed
a similar moderate increase in the protein level of NPC1
(about 1.4-fold, data not shown).
To investigate whether the psychotropic drug-mediated
transcriptional activation of cholesterol transport genes
was specific for the GaMg cells, we exposed two other CNS
cell lines to clozapine and haloperidol. In cultured human
astrocytoma cells (CCF-STTG1), both haloperidol and
clozapine significantly up-regulated ApoE, NPC1 and
NPC2 at 24 hours of incubation (n = 3; Figure 2). The
maximal response was recorded for the expression of
ApoE, which reached a 2.4- (p = 0.001) and 2.6-fold (p =
0.008) increase in the mRNA level after exposure to cloz-
apine (25 μM) and haloperidol (25 μM), respectively.
This drug-induced effect on cholesterol transport/export
was also observed in cultured human neuroblastoma cells
(SH-SY5Y), with clozapine (25 μM) and haloperidol (25
μM) enhancing the expression of ApoE about 1.9-fold (p =
0.007) and 2.5-fold (p = 0.001) at 24 hours, respectively.
In contrast, there was apparently no change in the NPC1
mRNA level, and the NPC2 gene was not expressed in
quantifiable amounts in the SH-SY5Y cells (data not
shown).
The liver is a major site for peripheral control of lipid
homeostasis, and we therefore also examined the expres-
sion of cholesterol transport genes in cultured humanBMC Pharmacology 2009, 9:10 http://www.biomedcentral.com/1471-2210/9/10
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Table 1: The effects of psychotropic drugs on the expression of cholesterol biosynthesis and transport genes in cultured human glioma 
(GaMg) cells. 
HMGCR APOE ABCA1 NPC1 NPC2 LXRα LXRβ
Clozapine (25 μM)
6 h 2.4 ± 0.1** 1.2 ± 0.1 1.0 ± 0.02 1.1 ± 0.04 1.2 ± 0.1 1.2 ± 0.1 1.2 ± 0.03*
12 h 2.2 ± 0.1** 1.8 ± 0.1** 1.5 ± 0.1 1.1 ± 0.03 1.3 ± 0.01* 1.0 ± 0.1 1.0 ± 0.03
24 h 2.1 ± 0.1** 2.2 ± 0.2** 1.2 ± 0.2 1.6 ± 0.1* 1.9 ± 0.1** 1.5 ± 0.3 1.4 ± 0.02**
48 h 2.2 ± 0.1** 4.5 ± 0.1** 2.6 ± 0.2** 2.5 ± 0.1** 2.6 ± 0.1** 1.1 ± 0.04 1.3 ± 0.02**
Olanzapine (10 μM)
6 h 1.8 ± 0.3* 1.2 ± 0.1 0.9 ± 0.2 1.2 ± 0.2 0.9 ± 0.3 1.1 ± 0.02 1.2 ± 0.09
12 h 1.3 ± 0.05** 1.1 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 1.0 ± 0.02 0.8 ± 0.03* 1.1 ± 0.06
24 h 1.4 ± 0.06** 1.5 ± 0.4 1.4 ± 0.06** 1.3 ± 0.05** 1.3 ± 0.02** 1.0 ± 0.1 1.3 ± 0.04*
48 h 1.1 ± 0.05* 1.5 ± 0.1* 1.2 ± 0.02** 1.0 ± 0.1 1.2 ± 0.04** 1.1 ± 0.05 1.0 ± 0.04
Haloperidol (10 μM)
6 h 2.1 ± 0.2** 1.2 ± 0.1 0.6 ± 0.06** 1.2 ± 0.1 1.0 ± 0.1 0.9 ± 0.07 1.1 ± 0.01
12 h 2.1 ± 0.1** 1.5 ± 0.2 0.3 ± 0.03** 1.1 ± 0.02* 1.2 ± 0.05* 0.6 ± 0.07** 0.8 ± 0.07*
24 h 2.2 ± 0.04** 2.3 ± 0.2** 0.3 ± 0.03** 1.7 ± 0.04** 1.8 ± 0.04** 1.1 ± 0.05 1.2 ± 0.3
48 h 1.8 ± 0.01** 2.4 ± 0.2** 0.3 ± 0.04** 1.5 ± 0.07** 1.8 ± 0.06** 1.0 ± 0.03 1.1 ± 0.04
Imipramine (10 μM)
6 h 2.0 ± 0.1** 1.2 ± 0.1 0.7 ± 0.2* 1.1 ± 0.1 0.8 ± 0.3 1.0 ± 0.07 1.1 ± 0.06
12 h 2.1 ± 0.04** 1.4 ± 0.1 0.6 ± 0.2** 1.1 ± 0.1 1.2 ± 0.03* 0.9 ± 0.09 1.1 ± 0.04
24 h 2.3 ± 0.05** 3.4 ± 0.3** 1.8 ± 0.09** 1.7 ± 0.04** 2.1 ± 0.07** 1.8 ± 0.4 1.3 ± 0.04*
48 h 1.6 ± 0.07** 2.6 ± 0.2** 1.0 ± 0.1 1.5 ± 0.01* 2.2 ± 0.08** 1.1 ± 0.05 1.2 ± 0.05
The expression of HMGCR, ApoE, ABCA1, NPC1, NPC2, LXRα, and LXRβ was examined in GaMg cells exposed to clozapine (25 μM), olanzapine (10 
μM), haloperidol (10 μM) or imipramine (10 μM) for 6, 12, 24 and 48 hours. The relative level of gene expression was measured by Q-RT-PCR and 
normalised against vehicle exposed culture at each timepoint. The data represent mean ± SEM of four independent replicates. * indicates p < 0.05 
and ** indicates p < 0.01 as compared to vehicle-exposed cells at the given time.
The relative gene expression and protein levels of ApoE in psychotropic drug-exposed human glioma (GaMg) cells Figure 1
The relative gene expression and protein levels of ApoE in psychotropic drug-exposed human glioma (GaMg) 
cells. Left panel: The relative level of ApoE mRNA, measured by Q-RT-PCR after 24 hours exposure, of 1 μM, 10 μM or 25 
μM of drug as compared to vehicle-exposed controls. The bars represent mean values ± SEM (n = 3). Right panel: The protein 
level of ApoE determined by western blotting in GaMg cells exposed to 25 μM of the drug (clozapine, olanzapine, haloperidol 
and imipramine) or vehicle for 24 hours. The data are normalized relative to the level of beta-actin, showing mean values ± 
SEM (n = 3) of the ratio between the drug- and vehicle-exposed cells. * indicates p < 0.05, ** indicates p < 0.01.BMC Pharmacology 2009, 9:10 http://www.biomedcentral.com/1471-2210/9/10
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HepG2 hepatoma cells. At 25 μM, clozapine, olanzapine,
haloperidol and imipramine all mediated about 3-fold
up-regulation of ApoE gene expression, with imipramine
as the most potent drug (Figure 3). In addition, ABCA1
gene expression was significantly up-regulated in both the
clozapine- and haloperidol exposed cells. HepG2 is one of
few cell lines expressing the NPC-related protein NPC1L1.
We found a significant 2-fold up-regulation of the
NPC1L1 gene expression by clozapine- and imipramine
exposure (Figure 3). The protein level of ApoE was also
significantly increased (2.1-3.0-fold, p < 0.05) for all drugs
at 25 μM concentration, as shown in Figure 3, right panel.
Discussion
In this study, we have shown how three antipsychotic
drugs (clozapine, olanzapine and haloperidol) and one
tricyclic antidepressant drug (imipramine) increase the
expression of central genes involved in cellular cholesterol
transport and export. A transcriptional response was
observed in all human cell lines (GaMg glioblastoma,
CCF-STTG1 astrocytoma, SH-SY5Y neuroblastoma and
HepG2 hepacytoma cells) examined, although with vari-
ous selections of drugs and concentrations and with some
notable differences. The up-regulation of the LXR target
The relative expression levels of ApoE, NPC1 and NPC2 in  psychotropic drug-exposed cultured human astrocytoma  (CFF-STTG1) cells Figure 2
The relative expression levels of ApoE, NPC1 and 
NPC2 in psychotropic drug-exposed cultured human 
astrocytoma (CFF-STTG1) cells. CFF-STGG1 cells were 
exposed to 25 μM of clozapine or haloperidol for 24 hours. 
The data represents mean values ± SEM (n = 3). * indicates p 
< 0.05, ** indicates p < 0.01.
The relative expression levels of ApoE, ABCA1, NPC1L1 and protein levels of ApoE in psychotropic drug-exposed cultured  human hepatoma (HepG2) cells Figure 3
The relative expression levels of ApoE, ABCA1, NPC1L1 and protein levels of ApoE in psychotropic drug-
exposed cultured human hepatoma (HepG2) cells. Left panel: Gene expression levels in HepG2 cells were exposed to 
25 μM of clozapine, olanzapine, haloperidol or imipramine, for 24 hours. The data represents mean values ± SEM (n = 4). Right 
panel: The protein level of ApoE determined by western blotting in HepG2 cells exposed to 25 μM of the drug (clozapine, 
olanzapine, haloperidol and imipramine) or vehicle for 24 hours. The data are normalized relative to the level of beta-actin, 
showing mean values ± SEM (n = 3) of the ratio between the drug- and vehicle-exposed cells. * indicates p < 0.05, ** indicates 
p < 0.01.BMC Pharmacology 2009, 9:10 http://www.biomedcentral.com/1471-2210/9/10
Page 5 of 7
(page number not for citation purposes)
genes ApoE, NPC1 and NPC2 was not evident before 24 to
48 hours of drug exposure, being clearly delayed as com-
pared to the activation of SREBP-controlled lipid biosyn-
thesis, thereby indicating that the increased expression of
cholesterol transport genes is secondary to the SREBP-
mediated response. Also, the increase in LXR transcripts
was modest. This observation is in line with data showing
that the LXR transcription factor can be activated by de
novo  synthesized oxysterols [19]. The drug-induced
increase in gene expression also produced a moderate ele-
vation of intracellular ApoE protein levels in GaMg and
HepG2 cells.
Changes in apolipoprotein E and D levels in the CNS have
previously been reported in patients with schizophrenia
and bipolar disorder [20,21]. The psychotropic drug-
induced activation of ApoE reported here is compatible
with clinical data showing increased ApoE levels after
treatment with mood-stabilizing and antipsychotic drugs
(although only a trend for the latter case), whereas
untreated patients with schizophrenia spectrum- and
bipolar disorder have decreased levels [22]. Our findings
may in part explain the mechanism behind the observed
changes in ApoE levels.
Involvement of myelin- and oligodendrocyte (glial)
abnormalities is suggested to play an important role in the
etiology of schizophrenia, bipolar disorder and unipolar
depression [8,10,23,24]. ApoE together with cholesterol is
essential in generation and maintenance of myelin [5]
and these factors have also been demonstrated to com-
prise a rate-limiting glia-derived growth factor important
in the formation of synapses and dendrite maturation in
cultured neuronal cells [6,25]. A recent study found that
polymorphisms in the SREBPF1 and SREBF2 genes are
associated with schizophrenia, suggesting that variation
in lipid biosynthesis affects disease susceptibility [26].
These genes encode the SREBP transcription factors that
control the biosynthesis of cholesterol and fatty acids.
Due to restricted transport of lipoproteins across the
blood-brain barrier, a complete machinery of both choles-
terol production and transport is needed to maintain cho-
lesterol homeostasis in the CNS [5]. We found that LXR-
controlled intracellular cholesterol transport proteins
investigated were up-regulated by the psychotropic drugs.
ABCA1 is primarily involved in the formation of HDL-
particles and this process is a rate-limiting step in cellular
cholesterol efflux and reverse cholesterol transport [27].
Interestingly, clozapine and haloperidol induced an up-
and down-regulation of ABCA1 expression in GaMg-cells
respectively, but this divergent action was not observed in
HepG2-cells. Enhancement of ABCA1 expression requires
a potent activation of both LXR and SREBP [28], whereas
an imbalanced stimulation of these transcription factors
may lead to down-regulation of ABCA1  expression
[29,30]. A transcriptional response with up-regulation of
many lipid transport genes, except for ABCA1, is similar to
the expression profile seen in Niemann Pick type C1-
knock-out mice, leading to perturbed myelin structure
and neurological symptoms due to accumulation of cho-
lesterol in lysosomes/endosomes [31]. Treatment with
LXR-agonists and induction of ABCA1  in these NPC1
knock-out animals reduced neuroinflammation, attenu-
ated neurodegeneration, and prolonged their lifespan
[31]. Recent studies show that some atypical antipsychotic
drugs as well as the antidepressant drug imipramine affect
myelination [9,32,33] and neuroplasticity [34], but the
underlying molecular mechanisms remain unknown.
Although care should be taken when extrapolating data
from cultured cancer cells to in vivo situation, the effect of
psychotropic drugs on lipid biosynthesis along with ele-
vated ApoE expression and cholesterol transport could
represent an important psychopharmacological effect of
these drugs.
Many psychotropic agents have high propensity to induce
metabolic adverse effects, such as weight gain and dyslip-
idemia, which represent major a clinical problem in the
treatment of psychiatric patients [35,36]. In a clinical set-
ting, we have demonstrated that, in line with our initial
findings in cultured cells, the expression of SREBP-con-
trolled fatty-acid biosynthesis genes (FASN and SCD) is
increased in blood cells of olanzapine-treated patients as
compared to unmedicated controls [15]. In addition, a
variant of the INSIG2  gene in the SREBP-system, was
found to be associated with antipsychotic drug-induced
weight gain [37]. Activation of SREBP- and LXR-transcrip-
tion factors can alter body cholesterol homeostasis, not
only through production and export, but also via changes
in intestinal cholesterol absorption. The Niemann-Pick
type C1-like 1 (NPC1L1) gene, which was up-regulated in
the HepG2 hepatoma cells by several psychotropic drugs,
is essential for intestinal cholesterol absorption [38]. Our
present data raise the possibility that the drug-mediated
effects on LXR-pathways are involved in the molecular
mechanisms of drug-induced weight gain and dyslipi-
demia, since LXR-controlled genes influence lipid trans-
port from peripheral tissues to the bloodstream.
Interestingly, an association has been shown between
clinical effect and weight gain in clozapine-treated
patients [39] and another study suggested that increased
serum lipid levels predicts the clinical response to clozap-
ine treatment [40].
Conclusion
Our data show as a proof-of-principle that psychotropic
drug-induced stimulation of cellular lipid biosynthesis in
vitro is followed by a transcriptional activation of choles-
terol transport and -efflux, including ApoE. Such drug-
effects could influence myelin maintenance, synaptogen-BMC Pharmacology 2009, 9:10 http://www.biomedcentral.com/1471-2210/9/10
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esis and drug-induced metabolic disturbances. Since our
data are obtained in cultured cells, further research is
needed to explore if these processes are also present in
vivo.
Methods
Cell cultures and drug exposure
Four human cell lines were used in this study: glioblast-
oma- (GaMg), astrocytoma- (CCF-STTG1), neuroblast-
oma- (SH-SY5Y) and hepatocellular carcinoma (HepG2)
cells. GaMg was obtained from an in-house source and
cultured as previously described [2]. CCF-STTG1 (catalog
no. CRL-1718), SH-SY5Y (catalog no. CRL-2266) and
HepG2 (catalog no. HB-8065) were purchased from
ATCC and cultured according to the manufacturer's rec-
ommendations http://www.atcc.org. All cells were grown
in monolayer in 6-well plates (TPP supplied by Med-
probe, Oslo, Norway) in 5% CO2 at 37°C for 24 hours
before adding fresh medium with drug or vehicle. Cell
cultures were exposed to haloperidol (Sigma Aldrich, St
Louis, USA), clozapine (Sigma Aldrich, St Louis, USA),
olanzapine (Toronto Research Chemicals, Toronto, Can-
ada), imipramine (ICN Biomedicals, Irvine, USA) or vehi-
cle (6 μg/ml lactic acid) equal to solvent.
Gene expression
Total RNA was extracted using the ABI PRISM™ 6100
Nucleic Acid PrepStation (Applied Biosystems, Foster
City, USA), quality-controlled by Agilent Bioanalyzer
2100 (Agilent Technologies, Palo Alto, USA) and quanti-
fied using Nanodrop ND-1000 spectrophotometer (Nan-
odrop Technologies, Delaware, USA). All RNA samples
were stored at -80°C until use. cDNA synthesis and quan-
titative real-time PCR (Q-RT-PCR) was performed with
Taqman Gold kit from Applied Biosystems and run on the
ABI PRISM 7900HT sequence detector as described previ-
ously [2]. Primers (Sigma Genosys, Haverhill, UK) used in
this study: HMGCR  (NM_000859): FWD 5'-tgaagcttt-
gccctttttcctac-3' REV 5'-attttcccttacttcatcctgtgag-3'; ApoE
(NM_000041): FWD 5'-agctcccaggtcacccag-3' REV 5'-cac-
cggggtcagttgttcc-3'; ABCA1 (NM_005502): FWD 5'-tccag-
gccagtacggaattc-3' REV 5'-actttcctcgccaaaccagtag-3'; LXRα
(NM_005693): FWD 5'-aagccctgcatgcctacgt-3' REV 5'-
gtgggaacatcagtcggtcat-3';  LXRβ  (NM_007121): FWD 5'-
gagggagcagtgcgtcctt-3' REV 5'-gctgttgtttccgaatcttcttc-3'.
NPC1, NPC2 and  NPC1L1  primers were purchased as
Assay on Demand (Applied Biosystems Inc, Foster City,
USA), assay number Hs00264835_m1 (Nm_002713),
Hs00197565_m1 (Nm_006432.5) and Hs00203602_m1
(Nm_001101648.1 and Nm_013389.2), respectively.
Immunoblot analysis
For western blot experiments, the cell culture medium was
supplemented to contain 20% FBS for three hours prior to
addition of the drugs or vehicle, in order to reduce the
basal level of SREBP-controlled lipid biosynthesis as
described previously [1,3]. Collection of total cell protein
was performed by washing the adherent cells twice with
cold PBS before adding RIPA lysis buffer (containing 15
mM NaCl, 50 mM TRIS, 0.5% sodium deoxycholate, 1%
Np-40 and 0.1% SDS) with protease inhibitor (Roche
Diagnostics, Indianapolis, USA). The cell lysates were
standardized according to their protein content as deter-
mined by the Bio-Rad technique (Bio-Rad Laboratories,
Richmond, USA) and subjected to SDS-PAGE using
NuPage gels and nitrocellulose membranes on the West-
ern Breeze system (Invitrogen, New York, USA), according
to the manufacturer's recommendations. The membranes
were incubated for three hours with purified monoclonal
anti-human mouse antibody against β-actin (Nordic
Biosite, Täby, Sweden), washed twice and then incubated
overnight at 4°C with purified monoclonal anti-human
mouse antibodies against ApoE (BD Biosciences
Pharmingen, San Diego, USA) or anti-human mouse anti-
bodies against NPC1 (Zymed, San Francisco, USA). The
blots were probed with a common secondary antibody
solution, followed by detection using Chemilumines-
cence reagent (Invitrogen, New York, USA) according to
the manufacturer's instructions. Quantification of western
blots was performed by densitometry and image scanning
with Fuji Las-1000 luminescent image analyzer (Fuji Film
Co, Fuji, Japan) and Image Gauge v4.0 software (Fuji).
Statistical analysis
All quantitative real-time PCR data were tested using one-
way ANOVA with Dunnett's 2-sided post-hoc test in SPSS
14.0. Two-sided student t-test with unequal variances
assumed was used to test the statistical significance of the
western blot quantification. The threshold for statistical
significance was set at p = 0.05.
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